Current and future management of psoriasis (Q28238060)

Adherence to treatment in patients with psoriasis.

Europe PubMed Central

title

Current and future management of psoriasis (English)

0 references

author

Christopher Griffiths

series ordinal

2

object named as

Christopher E M Griffiths

0 references

author name string

Alan Menter

series ordinal

1

0 references

language of work or name

English

0 references

publication date

21 July 2007

0 references

published in

The Lancet

0 references

volume

370

0 references

page(s)

272-84

0 references

issue

9583

0 references

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961129-5

7 January 2021

Psychological distress impairs clearance of psoriasis in patients treated with photochemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961129-5

7 January 2021

A cognitive-behavioural symptom management programme as an adjunct in psoriasis therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961129-5

7 January 2021

Correlation of the vasoconstriction assay and clinical activity in psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961129-5

7 January 2021

Remission and relapse of chronic plaque psoriasis treated once a week with clobetasol propionate occluded with a hydrocolloid dressing versus twice daily treatment with clobetasol propionate alone

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961129-5

7 January 2021

Topical preparations for the treatment of psoriasis: a systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961129-5

7 January 2021

The new topical ascomycin derivative SDZ ASM 981 does not induce skin atrophy when applied to normal skin for 4 weeks: a randomized, double-blind controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961129-5

7 January 2021

Tacrolimus ointment does not affect collagen synthesis: results of a single-center randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961129-5

7 January 2021

Intermittent Corticosteroid Maintenance Treatment of Psoriasis: A Double-Blind Multicenter Trial of Augmented Betamethasone Dipropionate Ointment in a Pulse Dose Treatment Regimen

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961129-5

7 January 2021

Intra-individual comparison of the cutaneous safety and efficacy of calcitriol 3 microg g(-1) ointment and calcipotriol 50 microg g(-1) ointment on chronic plaque psoriasis localized in facial, hairline, retroauricular or flexural areas.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961129-5

7 January 2021

Systematic review of comparative efficacy and tolerability of calcipotriol in treating chronic plaque psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961129-5

7 January 2021

Calcipotriol for psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961129-5

7 January 2021

Long-term use of topical calcipotriol in chronic plaque psoriasis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961129-5

7 January 2021

Long-term efficacy and safety of tacalcitol ointment in patients with chronic plaque psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961129-5

7 January 2021

The effect of addition of calcipotriol ointment (50 micrograms/g) to acitretin therapy in psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961129-5

7 January 2021

A novel therapeutic approach to psoriasis with combination calcipotriol ointment and very low-dose cyclosporine: results of a multicenter placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961129-5

7 January 2021

Calcipotriol improves the efficacy of cyclosporine in the treatment of psoriasis vulgaris

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961129-5

7 January 2021

Calcitriol 3 microg g-1 ointment in combination with ultraviolet B phototherapy for the treatment of plaque psoriasis: results of a comparative study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961129-5

7 January 2021

Calcipotriol cream combined with twice weekly broad-band UVB phototherapy: a safe, effective and UVB-sparing antipsoriatric combination treatment. The Canadian Calcipotriol and UVB Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961129-5

7 January 2021

Combination TL01 ultraviolet B phototherapy and topical calcipotriol for psoriasis: a prospective randomized placebo-controlled clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961129-5

7 January 2021

Calcipotriol improves the response of psoriasis to PUVA.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961129-5

7 January 2021

A combination therapy of calcipotriol cream and PUVA reduces the UVA dose and improves the response of psoriasis vulgaris.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961129-5

7 January 2021

Calcipotriene ointment and halobetasol ointment in the long-term treatment of psoriasis: effects on the duration of improvement

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961129-5

7 January 2021

A new calcipotriol/betamethasone formulation with rapid onset of action was superior to monotherapy with betamethasone dipropionate or calcipotriol in psoriasis vulgaris

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961129-5

7 January 2021

Early onset of action and efficacy of a combination of calcipotriene and betamethasone dipropionate in the treatment of psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961129-5

7 January 2021

A 52-week randomized safety study of a calcipotriol/betamethasone dipropionate two-compound product (Dovobet/Daivobet/Taclonex) in the treatment of psoriasis vulgaris

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961129-5

7 January 2021

Tazarotene cream in the treatment of psoriasis: Two multicenter, double-blind, randomized, vehicle-controlled studies of the safety and efficacy of tazarotene creams 0.05% and 0.1% applied once daily for 12 weeks

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961129-5

7 January 2021

Combination of calcipotriene (Dovonex) ointment and tazarotene (Tazorac) gel versus clobetasol ointment in the treatment of plaque psoriasis: a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961129-5

7 January 2021

Tazarotene 0.1% gel plus corticosteroid cream in the treatment of plaque psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961129-5

7 January 2021

Instrumental evaluation of retinoid-induced skin irritation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961129-5

7 January 2021

Tazarotene gel, a new retinoid, for topical therapy of psoriasis: vehicle-controlled study of safety, efficacy, and duration of therapeutic effect

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961129-5

7 January 2021

Topical tacrolimus is not effective in chronic plaque psoriasis. A pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961129-5

7 January 2021

Tacrolimus ointment is effective for facial and intertriginous psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961129-5

7 January 2021

Pimecrolimus cream 1% in the treatment of intertriginous psoriasis: a double-blind, randomized study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961129-5

7 January 2021

Topical tacrolimus ointment combined with 6% salicylic acid gel for plaque psoriasis treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961129-5

7 January 2021

The anti-psoriatic drug anthralin accumulates in keratinocyte mitochondria, dissipates mitochondrial membrane potential, and induces apoptosis through a pathway dependent on respiratory competent mitochondria.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961129-5

7 January 2021

The approach to psoriasis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961129-5

7 January 2021

The effects of topical corticosteroids and a coal tar preparation on dithranol-induced irritation in patients with psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961129-5

7 January 2021

Combining lesional short-contact dithranol therapy of psoriasis with a potent topical corticosteroid

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961129-5

7 January 2021

Calcipotriol plus short-contact dithranol: a novel topical combination therapy for chronic plaque psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961129-5

7 January 2021

The efficacy, safety and tolerance of calcitriol 3 microg/g ointment in the treatment of plaque psoriasis: a comparison with short-contact dithranol

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961129-5

7 January 2021

The effect of triethanolamine application on anthralin-induced inflammation and therapeutic effect in psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961129-5

7 January 2021

A novelliposomal formulation of dithranol for psoriasis: preliminary results

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961129-5

7 January 2021

Comparison of calcipotriol and coal tar in conjunction with sun exposure in chronic plaque psoriasis: a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961129-5

7 January 2021

Genotoxic effect of Goeckerman regimen of psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961129-5

7 January 2021

Action Spectrum for Phototherapy of Psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961129-5

7 January 2021

A controlled study of ultraviolet A sunbed treatment of psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961129-5

7 January 2021

Components of the Goeckerman Regimen

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961129-5

7 January 2021

The Validity and Practicality of Sun-Reactive Skin Types I Through VI

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961129-5

7 January 2021

Genital tumors among men with psoriasis exposed to psoralens and ultraviolet A radiation (PUVA) and ultraviolet B radiation. The Photochemotherapy Follow-up Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961129-5

7 January 2021

A randomized, observer-blinded trial of twice vs. three times weekly narrowband ultraviolet B phototherapy for chronic plaque psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961129-5

7 January 2021

Non-Melanoma Skin Cancer Occurring in Patients Treated With PUVA Five to Ten Years After First Treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961129-5

7 January 2021

The risk of melanoma in association with long-term exposure to PUVA.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961129-5

7 January 2021

A comparison of bathwater and oral delivery of 8-methoxypsoralen in PUVA therapy for plaque psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961129-5

7 January 2021

Shower PUVA: a novel variant of photochemotherapy. Distribution of photosensitivity and accumulation of trioxsalen in the skin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961129-5

7 January 2021

Narrowband UVB and cream psoralen-UVA combination therapy for plaque-type psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961129-5

7 January 2021

Consensus conference: acitretin in combination with UVB or PUVA in the treatment of psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961129-5

7 January 2021

Traditional therapies in the management of moderate to severe chronic plaque psoriasis: an assessment of the benefits and risks.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961129-5

7 January 2021

Efficacy and safety of cyclosporine versus methotrexate in severe psoriasis: a study from north India

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961129-5

7 January 2021

Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961129-5

7 January 2021

Treatment of gastrointestinal symptoms associated with methotrexate therapy for psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961129-5

7 January 2021

Folic acid supplementation during treatment of psoriasis with methotrexate: a randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961129-5

7 January 2021

Adult and two children with fetal methotrexate syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961129-5

7 January 2021

Clinical, laboratory, radiographic, and histopathologic features of methotrexate-associated lung injury in patients with rheumatoid arthritis: a multicenter study with literature review

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961129-5

7 January 2021

Methotrexate in psoriasis: consensus conference

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961129-5

7 January 2021

Replacement of routine liver biopsy by procollagen III aminopeptide for monitoring patients with psoriasis receiving long-term methotrexate: a multicentre audit and health economic analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961129-5

7 January 2021

Combination treatment with methotrexate and cyclosporin for severe recalcitrant psoriasis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961129-5

7 January 2021

Isotretinoin vs etretinate therapy in generalized pustular and chronic psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961129-5

7 January 2021

Efficacy and safety of oral retinoids in psoriasis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961129-5

7 January 2021

Combined treatment of psoriasis with acitretin and UVB phototherapy compared with acitretin alone and UVB alone

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961129-5

7 January 2021

Photochemotherapy for severe psoriasis without or in combination with acitretin: A randomized, double-blind comparison study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961129-5

7 January 2021

Conversion of acitretin to etretinate in psoriatic patients is influenced by ethanol

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961129-5

7 January 2021

Osteoporosis is a toxic effect of long-term etretinate therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961129-5

7 January 2021

Skeletal hyperostosis and extraosseous calcification in patients receiving long-term etretinate (Tigason).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961129-5

7 January 2021

Long-term safety and efficacy of low-dose cyclosporin A in severe psoriatic arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961129-5

7 January 2021

Cross talk among calcineurin, Sp1/Sp3, and NFAT in control of p21(WAF1/CIP1) expression in keratinocyte differentiation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961129-5

7 January 2021

Ciclosporin in psoriasis clinical practice: an international consensus statement

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961129-5

7 January 2021

Long-term low-dose cyclosporine therapy for severe psoriasis: effects on renal function and structure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961129-5

7 January 2021

Risk of malignancies in psoriasis patients treated with cyclosporine: a 5 y cohort study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961129-5

7 January 2021

Dimethylfumarate is a potent inducer of apoptosis in human T cells

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961129-5

7 January 2021

Treatment of psoriasis with fumaric acid esters: results of a prospective multicentre study. German Multicentre Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961129-5

7 January 2021

Fumaric acid esters for severe psoriasis: a retrospective review of 58 cases.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961129-5

7 January 2021

Long-term safety aspects of systemic therapy with fumaric acid esters in severe psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961129-5

7 January 2021

Treatment Of Psoriasis With Oral Mycophenolic Acid

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961129-5

7 January 2021

6-Thioguanine treatment of psoriasis: experience in 81 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961129-5

7 January 2021

Current concepts and review of alefacept in the treatment of psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961129-5

7 January 2021

Alefacept reduces infiltrating T cells, activated dendritic cells, and inflammatory genes in psoriasis vulgaris

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961129-5

7 January 2021

An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961129-5

7 January 2021

Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961129-5

7 January 2021

Current concepts and review of efalizumab in the treatment of psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961129-5

7 January 2021

Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961129-5

7 January 2021

Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961129-5

7 January 2021

The treatment of psoriasis and psoriatic arthritis with etanercept: practical considerations on monotherapy, combination therapy, and safety

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961129-5

7 January 2021

Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961129-5

7 January 2021

Etanercept as monotherapy in patients with psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961129-5

7 January 2021

A randomized trial of etanercept as monotherapy for psoriasis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961129-5

7 January 2021

Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961129-5

7 January 2021

Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961129-5

7 January 2021

Psoriasis and its treatment with infliximab-mediated tumor necrosis factor alpha blockade

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961129-5

7 January 2021

Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961129-5

7 January 2021

Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961129-5

7 January 2021

Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961129-5

7 January 2021

Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961129-5

7 January 2021

Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961129-5

7 January 2021

Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961129-5

7 January 2021

Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961129-5

7 January 2021

A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961129-5

7 January 2021

British Association of Dermatologists guidelines for use of biological interventions in psoriasis 2005

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961129-5

7 January 2021

[S3-Guidelines for the therapy of psoriasis vulgaris].

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961129-5

7 January 2021

A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961129-5

7 January 2021

Oral pimecrolimus in the treatment of moderate to severe chronic plaque-type psoriasis: a double-blind, multicentre, randomized, dose-finding trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961129-5

7 January 2021

A randomized, multicenter, double-blind, placebo-controlled phase 2 trial of ISA247 in patients with chronic plaque psoriasis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961129-5

7 January 2021

The potential of pharmacogenetics in optimizing the use of methotrexate for psoriasis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961129-5

7 January 2021

Polymorphisms in Folate, Pyrimidine, and Purine Metabolism Are Associated with Efficacy and Toxicity of Methotrexate in Psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961129-5

7 January 2021

Interaction between genetic control of vascular endothelial growth factor production and retinoid responsiveness in psoriasis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961129-5

7 January 2021

Controlled study of excimer and pulsed dye lasers in the treatment of psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961129-5

7 January 2021

10.1016/S0140-6736(07)61129-5

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

4574036

4574036

1 reference

Consolidated OpenCitations Corpus – April 2017

Consolidated OpenCitations Corpus – April 2017

1 reference